GB1581234A - 11a - amino - 3a - hydroxysteroids - Google Patents

11a - amino - 3a - hydroxysteroids Download PDF

Info

Publication number
GB1581234A
GB1581234A GB13707/76A GB1370776A GB1581234A GB 1581234 A GB1581234 A GB 1581234A GB 13707/76 A GB13707/76 A GB 13707/76A GB 1370776 A GB1370776 A GB 1370776A GB 1581234 A GB1581234 A GB 1581234A
Authority
GB
United Kingdom
Prior art keywords
alpha
hydroxy
group
compounds
pregnan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB13707/76A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Operations UK Ltd
Original Assignee
Glaxo Operations UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Operations UK Ltd filed Critical Glaxo Operations UK Ltd
Priority to GB13707/76A priority Critical patent/GB1581234A/en
Priority to NL7703667A priority patent/NL7703667A/xx
Priority to JP3768077A priority patent/JPS52142056A/ja
Priority to NO771197A priority patent/NO771197L/no
Priority to AU23942/77A priority patent/AU517206B2/en
Priority to ZA00772029A priority patent/ZA772029B/xx
Priority to SE7703929A priority patent/SE7703929L/xx
Priority to PL19718677A priority patent/PL197186A1/xx
Priority to LU77064A priority patent/LU77064A1/xx
Priority to IE712/77A priority patent/IE45276B1/en
Priority to FI771046A priority patent/FI771046A7/fi
Priority to IL51816A priority patent/IL51816A/xx
Priority to DK148677A priority patent/DK148677A/da
Priority to BE176410A priority patent/BE853227A/xx
Priority to ES457507A priority patent/ES457507A1/es
Priority to DE19772715078 priority patent/DE2715078A1/de
Priority to IT48805/77A priority patent/IT1073232B/it
Priority to NZ183775A priority patent/NZ183775A/xx
Priority to FR7710271A priority patent/FR2347382A1/fr
Publication of GB1581234A publication Critical patent/GB1581234A/en
Priority to FR8110329A priority patent/FR2485020A1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB13707/76A 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids Expired GB1581234A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GB13707/76A GB1581234A (en) 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids
IE712/77A IE45276B1 (en) 1976-04-05 1977-04-04 11 -amino-3 hydroxy steroids
DK148677A DK148677A (da) 1976-04-05 1977-04-04 Fremgangsmade til fremstilling af anestetisk virksomme steroider
NO771197A NO771197L (no) 1976-04-05 1977-04-04 Fremgang}te for fremstilling av fysioisk aktive steroider
AU23942/77A AU517206B2 (en) 1976-04-05 1977-04-04 11a DISUBTITUTED AMINO STEROID DERIVATIVES
ZA00772029A ZA772029B (en) 1976-04-05 1977-04-04 Steroid anaesthetics
SE7703929A SE7703929L (sv) 1976-04-05 1977-04-04 Anestetika
PL19718677A PL197186A1 (pl) 1976-04-05 1977-04-04 Sposob wytwarzania steroidow
LU77064A LU77064A1 (enExample) 1976-04-05 1977-04-04
NL7703667A NL7703667A (nl) 1976-04-05 1977-04-04 Werkwijze voor het bereiden van een steroide met anesthetische werking.
FI771046A FI771046A7 (enExample) 1976-04-05 1977-04-04
IL51816A IL51816A (en) 1976-04-05 1977-04-04 Steroids,their preparation and pharmaceutical compositions containing them
JP3768077A JPS52142056A (en) 1976-04-05 1977-04-04 Production of steroid
BE176410A BE853227A (fr) 1976-04-05 1977-04-04 11alpha-amino, delta 4 ou delta 5 pregnanes et androstanes a groupe disubstitue
ES457507A ES457507A1 (es) 1976-04-05 1977-04-04 Un procedimiento para la preparacion de esteroides.
DE19772715078 DE2715078A1 (de) 1976-04-05 1977-04-04 Steroidderivate, verfahren zu deren herstellung und diese enthaltende zusammensetzungen
IT48805/77A IT1073232B (it) 1976-04-05 1977-04-04 Procedimento per preparare steroidi
NZ183775A NZ183775A (en) 1976-04-05 1977-04-04 Anaesthetic steroids
FR7710271A FR2347382A1 (fr) 1976-04-05 1977-04-05 11a-amino, d4 ou d5 pregnanes et androstanes a groupe amino disubstitue
FR8110329A FR2485020A1 (fr) 1976-04-05 1981-05-25 11a-amino,4 ou 5 pregnanes et androstanes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB13707/76A GB1581234A (en) 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids

Publications (1)

Publication Number Publication Date
GB1581234A true GB1581234A (en) 1980-12-10

Family

ID=10027931

Family Applications (1)

Application Number Title Priority Date Filing Date
GB13707/76A Expired GB1581234A (en) 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids

Country Status (19)

Country Link
JP (1) JPS52142056A (enExample)
AU (1) AU517206B2 (enExample)
BE (1) BE853227A (enExample)
DE (1) DE2715078A1 (enExample)
DK (1) DK148677A (enExample)
ES (1) ES457507A1 (enExample)
FI (1) FI771046A7 (enExample)
FR (2) FR2347382A1 (enExample)
GB (1) GB1581234A (enExample)
IE (1) IE45276B1 (enExample)
IL (1) IL51816A (enExample)
IT (1) IT1073232B (enExample)
LU (1) LU77064A1 (enExample)
NL (1) NL7703667A (enExample)
NO (1) NO771197L (enExample)
NZ (1) NZ183775A (enExample)
PL (1) PL197186A1 (enExample)
SE (1) SE7703929L (enExample)
ZA (1) ZA772029B (enExample)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044227A1 (en) * 1980-07-16 1982-01-20 Glaxo Group Limited 11-Alpha-amino androstanes, pharmaceutical compositions containing them and processes for their preparation
EP0066467A1 (en) * 1981-05-29 1982-12-08 Glaxo Group Limited 11-Alpha-amino-androstanes
EP0066468A1 (en) * 1981-05-29 1982-12-08 Glaxo Group Limited 11-Alpha-amino-androstanes
US4451405A (en) * 1981-03-02 1984-05-29 Glaxo Group Limited 11α-Amino-3β-hydroxy-androstanes
US5591733A (en) * 1987-08-25 1997-01-07 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5593983A (en) * 1993-12-02 1997-01-14 Akzo Nobel N.V. Substituted 2β-morpholino-androstane derivatives
CN105555277A (zh) * 2013-07-19 2016-05-04 萨奇治疗股份有限公司 神经活性类固醇化合物、组合物及其用途
EP3224269A4 (en) * 2014-11-27 2018-07-25 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2019126761A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2020264512A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
WO2020264495A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
RU2799448C2 (ru) * 2017-12-22 2023-07-05 Сейдж Терапьютикс, Инк. Композиции и способы лечения заболеваний центральной нервной системы
US11912738B2 (en) 2018-12-05 2024-02-27 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US11993628B2 (en) 2016-07-11 2024-05-28 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1171389B (it) * 1980-07-16 1987-06-10 Glaxo Group Ltd Composti amminosteroidi composizioni farmaceutiche che li contengono e procentimento per prepararli
FR2910002B1 (fr) * 2006-12-13 2009-01-30 Sanofi Aventis Sa Nouveau procede pour l'obtention diastereoselective d'une amine primaire chirale sur un steroide
JP2010037243A (ja) * 2008-08-04 2010-02-18 Mitsubishi Rayon Co Ltd ノルボルネンラクトンモノマーの製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2982775A (en) * 1957-05-06 1961-05-02 Schering Corp 11-oximino-, amino- and acylaminosteroids

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044227A1 (en) * 1980-07-16 1982-01-20 Glaxo Group Limited 11-Alpha-amino androstanes, pharmaceutical compositions containing them and processes for their preparation
US4451405A (en) * 1981-03-02 1984-05-29 Glaxo Group Limited 11α-Amino-3β-hydroxy-androstanes
EP0066467A1 (en) * 1981-05-29 1982-12-08 Glaxo Group Limited 11-Alpha-amino-androstanes
EP0066468A1 (en) * 1981-05-29 1982-12-08 Glaxo Group Limited 11-Alpha-amino-androstanes
US5591733A (en) * 1987-08-25 1997-01-07 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5593983A (en) * 1993-12-02 1997-01-14 Akzo Nobel N.V. Substituted 2β-morpholino-androstane derivatives
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US11912737B2 (en) 2013-04-17 2024-02-27 Sage Therpeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US12201640B2 (en) 2013-04-17 2025-01-21 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US10342810B2 (en) 2013-04-17 2019-07-09 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
EP3868382A1 (en) * 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105555277A (zh) * 2013-07-19 2016-05-04 萨奇治疗股份有限公司 神经活性类固醇化合物、组合物及其用途
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3021852A4 (en) * 2013-07-19 2017-03-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2014290400B2 (en) * 2013-07-19 2019-12-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12071453B2 (en) 2013-08-23 2024-08-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12473327B2 (en) 2014-06-18 2025-11-18 Sage Therapeutics, LLP Neuroactive steroids, compositions and uses thereof
US11780875B2 (en) 2014-06-18 2023-10-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10745436B2 (en) 2014-06-18 2020-08-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12065463B2 (en) 2014-10-16 2024-08-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11542297B2 (en) 2014-10-16 2023-01-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11530237B2 (en) 2014-10-16 2022-12-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12180248B2 (en) 2014-10-16 2024-12-31 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3719029A1 (en) * 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
EP3224269A4 (en) * 2014-11-27 2018-07-25 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11554125B2 (en) 2016-03-08 2023-01-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11993628B2 (en) 2016-07-11 2024-05-28 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
CN111741965A (zh) * 2017-12-22 2020-10-02 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
RU2799448C2 (ru) * 2017-12-22 2023-07-05 Сейдж Терапьютикс, Инк. Композиции и способы лечения заболеваний центральной нервной системы
WO2019126761A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN111741965B (zh) * 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
AU2018392093B2 (en) * 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11970514B2 (en) 2018-12-05 2024-04-30 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US11999765B2 (en) 2018-12-05 2024-06-04 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US12252509B2 (en) 2018-12-05 2025-03-18 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US12264177B2 (en) 2018-12-05 2025-04-01 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US12410210B2 (en) 2018-12-05 2025-09-09 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US11912738B2 (en) 2018-12-05 2024-02-27 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
WO2020264495A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2020264512A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders

Also Published As

Publication number Publication date
DK148677A (da) 1977-10-06
IL51816A (en) 1981-09-13
JPS52142056A (en) 1977-11-26
AU2394277A (en) 1978-10-12
LU77064A1 (enExample) 1979-01-18
NO771197L (no) 1977-10-06
NL7703667A (nl) 1977-10-07
ZA772029B (en) 1978-11-29
SE7703929L (sv) 1978-10-27
FR2485020A1 (fr) 1981-12-24
IT1073232B (it) 1985-04-13
PL197186A1 (pl) 1979-06-18
DE2715078A1 (de) 1977-10-13
NZ183775A (en) 1979-12-11
AU517206B2 (en) 1981-07-16
IE45276L (en) 1977-10-05
BE853227A (fr) 1977-10-04
ES457507A1 (es) 1978-03-16
FR2347382B1 (enExample) 1982-01-08
IL51816A0 (en) 1977-06-30
IE45276B1 (en) 1982-07-28
FR2347382A1 (fr) 1977-11-04
FI771046A7 (enExample) 1977-10-06

Similar Documents

Publication Publication Date Title
GB1581234A (en) 11a - amino - 3a - hydroxysteroids
CA1084903A (en) Anaesthetic steroids
US4192871A (en) Chemical compounds
US3983111A (en) Steroidal anaesthetics of the pregnane and 19-norpregnane series
DE3783007T2 (de) 9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate.
GB1581235A (en) 11a-amino-3a-hydroxy-steroids
US3989686A (en) Anaesthetic steroids of the androstane series and process for preparing same
CA1051868A (en) D-homo-20-keto-pregnanes
AU655858B2 (en) 17-spirofuran-3'-ylidene steroids
US4197296A (en) Androstanes
FI57114B (fi) Foerfarande foer framstaellning av nya vid cancerterapi anvaendbara terapeutiskt vaerdefulla enolestrar av steroider
IL38124A (en) 3alpha-hydroxy-20-keto-2beta-substituted pregnanes and anaesthetic compositions containing them
US3969345A (en) 20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof
US3084159A (en) 3-enol ethers of 3-oxo-delta-6-aminomethyl steroids and process for preparing same
US3882151A (en) Chemical compounds
Gardi et al. A simple route to steroid 17α, 20α, 21-triols and their 21-monoesters
US4330539A (en) Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof
EP0033561B1 (en) Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof, processes for their preparation and pharmaceutical compositions
US3461118A (en) 3beta-tetrahydrofuranyloxy - and 3beta-tetrahydropyranyloxyestra - 4,9(10) - dienes and -4,9(10),11-trienes,their preparation and intermediates thereof
US3398140A (en) Steroido [17. 16-c] pyrozoles and preparation thereof
US3351639A (en) 17-alkyl-20-keto substituted pregnenes, pregnadienes and methods of preparing the same
US4022892A (en) 17β-Ethynyl-3,17α-estradiol and derivatives thereof
US3377342A (en) 2', 2'-bistrifluoromethyloxetano(3', 4'; 16alpha, 17alpha)derivatives of 4-pregneno [3, 2-c]pyrazoles and 4, 6-pregnadieno [3, 2-c]pyrazoles
EP0014005A1 (en) Novel alkylated pregnanes, processes for their preparation and pharmaceutical compositions containing same
NO130476B (enExample)

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee